Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis

A S Taha, S McLaughlin, P J Holland, R W Kelly, R D Sturrock, R I Russell

Abstract

The synthesis of gastric and duodenal mucosal prostaglandin E₂, prostaglandin I₂, and thromboxane B₂ during a 60 minute incubation of biopsy specimens, the degree of endoscopic and histological damage, and the anti-inflammatory response were all studied after a four week, double blind study of therapeutic doses of two non-steroidal anti-inflammatory drugs, naproxen and etodolac, received by 27 patients with active rheumatoid arthritis (13 receiving naproxen, 14 etodolac). Prostaglandin values after treatment did not differ from the baseline levels when all the patients were analysed as one group. Subgroup analysis showed that naproxen suppressed gastric prostaglandin E₂ from a median of 29 to 9 ng/mg protein, duodenal prostaglandin E₂ from 34 to 11 ng/mg, and duodenal prostaglandin I₁ from 62 to 15 ng/mg protein. No overall suppression occurred with etodolac. Also, on the second assessment patients receiving naproxen had lower gastric and duodenal prostaglandin E₂ and prostaglandin I₁, but higher values of duodenal thromboxane B₂, than patients receiving etodolac. Both drugs had comparable anti-arthritic activity and caused microscopic gastritis in similar proportions of patients. No correlation was detected between prostaglandin values and the mucosal damage which developed in seven patients receiving naproxen (54%) and three receiving etodolac (21%).

These findings indicate that, unlike naproxen, etodolac does not seem to affect gastric or duodenal prostaglandin synthesis; other mechanisms of injury need to be considered.

Etodolac is a member of a new class of NSAIDs, the pyranocarboxylic acids; it has been reported to be better tolerated by the stomach than naproxen, a propionic acid derivative with established efficacy in arthritis, but both agents were reported to have a comparable anti-arthritic activity. An animal study suggested that the different effect of these two agents on the gastric prostaglandin synthesis by etodolac.

The purpose of this prospective, double blind, single centre study was to assess the effect of four weeks’ treatment with therapeutic doses of naproxen or etodolac in patients with active rheumatoid arthritis on gastroduodenal mucosal prostaglandin synthesis, anti-inflammatory activity, and endoscopic and histological changes.

Subjects, materials, and methods

PATIENTS WITH RHEUMATOID ARTHRITIS

The patients studied were 18–70 years with active rheumatoid arthritis according to the criteria of the American Rheumatism Association. Patients receiving second line agents—gold, penicillamine, or hydroxychloroquine but not sulphasalazine—were included if the drug treatment had been started six or more months before the start of the study and the doses had been unchanged for the last two months. Sulphasalazine was excluded because 5–10% of its 5-aminosalicylic acid component is absorbed, which might affect prostaglandin production, although there is no evidence for this. Subjects receiving NSAIDs underwent a washout period of at least five to seven days before receiving the study drugs, during which time paracetamol was used as an analgesic agent. Preliminary work at our units showed that there was no significant difference in gastric or duodenal mucosal prostaglandin synthesis between arthritic patients who had stopped receiving NSAIDs for four days and controls who were not receiving NSAIDs. Patients with abdominal complaints, a history of peptic ulceration, or any systemic diseases were excluded. Those taking cytotoxic agents, steroids, or ulcer healing drugs were also excluded.

STUDY DRUGS

Naproxen 500 mg twice daily and etodolac 300 mg twice daily were given in a double blind, randomised design for a period of four weeks,
with paracetamol used as a baseline analgesic. Compliance was checked by a tablet count.

ASSESSMENTS

Assessments were made on two visits—just before the start of the study and on completion four weeks later. They included a general medical history and examination, assessment of the activity of the rheumatoid arthritis, and endoscopy. Rheumatoid disease activity was assessed by measuring the erythrocyte sedimentation rate, grip strength (mmHg), Ritchie articular index, duration of morning stiffness, and both the patients' and investigators' evaluation of the global condition. Endoscopy was performed after giving 5–15 mg dexamethasone intravenously. Endoscopic abnormalities were graded according to a (0–5) scale modified from Lanza et al. 

Patients showing abnormal endoscopic findings at the initial visit were not admitted to the study. On both visits biopsy specimens weighing 5–10 mg were taken from healthy looking mucosa in the gastric antrum and the first part of the duodenum for prostaglandin assays and for histology. All assessments were done under double blind conditions. Suitable patients were given the study drugs within 12 hours of completing the initial assessment.

HISTOLOGY

Specimens were fixed in formalin buffered saline, embedded in paraffin wax, and 5 µm sections prepared for light microscopy. Sections were stained with haematoxylin and eosin. Histological appearances were broadly divided into mild or severe inflammation: mild inflammation referred to the presence of few inflammatory cells in the lamina propria, while severe inflammation meant that there was extensive inflammatory infiltration of the lamina propria, glands, and crypts.
or after NSAID treatment. Significant differences became noticeable when patients were classified according to whether they had received naproxen or etodolac (tables 1–3); gastric prostaglandin E2, duodenal prostaglandin E2 and prostaglandin I2 were all suppressed by naproxen. Etodolac seemed to have no effect on prostaglandin concentrations. In addition, compared with etodolac patients on the second assessment, naproxen patients had lower gastric and duodenal prostaglandin E2 and prostaglandin I2 but higher values of duodenal thromboxane B2.

**ANTI-ARTHritic ACTIVITY**

Table 4 shows the improvement in the indices of rheumatoid disease activity; all variables improved after treatment but not necessarily to a significant degree, apart from the duration of morning stiffness (p<0.001) and the articular index (p<0.05). The overall results indicate that in this small group of patients naproxen and etodolac had similar anti-inflammatory efficacy.

**ENDOSCOPIC AND HISTOLOGICAL CHANGES**

The second endoscopy was abnormal in seven patients receiving naproxen (54%) with a median score of 2 (0–4), (interquartile ranges), compared with three patients receiving etodolac (21%) and a score of 0 (0–1) (p<0.05). Lesions developed

<table>
<thead>
<tr>
<th>Table 1: Gastric and duodenal prostaglandin E2, median (interquartile ranges), ng/mg protein, at baseline and after non-steroidal anti-inflammatory drug treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subjects</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>All rheumatoid patients (n=27)</td>
</tr>
<tr>
<td>Patients receiving naproxen (n=13)</td>
</tr>
<tr>
<td>Patients receiving etodolac (n=14)</td>
</tr>
</tbody>
</table>

Significant drop: *p<0.01 (compared with baseline values in the naproxen group and with values after treatment in patients receiving etodolac).

<table>
<thead>
<tr>
<th>Table 2: Gastric and duodenal prostaglandin I2 (6-oxo-prostaglandin F122), median (interquartile range), ng/mg protein, at baseline and after non-steroidal anti-inflammatory drug treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subjects</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>All rheumatoid patients (n=27)</td>
</tr>
<tr>
<td>Patients receiving naproxen (n=13)</td>
</tr>
<tr>
<td>Patients receiving etodolac (n=14)</td>
</tr>
</tbody>
</table>

Significant drop: *p<0.05 (compared with baseline values in the naproxen group and with gastric and duodenal values after treatment in patients receiving etodolac).

<table>
<thead>
<tr>
<th>Table 3: Gastric and duodenal thromboxane B2, median (interquartile ranges), ng/mg protein, at baseline and after non-steroidal anti-inflammatory drug treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subjects</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>All rheumatoid patients (n=27)</td>
</tr>
<tr>
<td>Patients receiving naproxen (n=13)</td>
</tr>
<tr>
<td>Patients receiving etodolac (n=14)</td>
</tr>
</tbody>
</table>

Significant rise: *p<0.05 (compared with etodolac).

<table>
<thead>
<tr>
<th>Table 4: Duration of morning stiffness, grip strength, articular index, and erythrocyte sedimentation (ESR) before and after treatment: median and interquartile ranges</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indices of activity</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Duration of morning stiffness (min)</td>
</tr>
<tr>
<td>Grip strength (mmHg)</td>
</tr>
<tr>
<td>Right hand</td>
</tr>
<tr>
<td>Left hand</td>
</tr>
<tr>
<td>Articular index</td>
</tr>
</tbody>
</table>

Significant improvement: *p<0.001; †p<0.01; ††p<0.05.
Effect of naproxen and etodolac on prostaglandins in RA

357

in the stomach in all 10 cases (seven naproxen, three etodolac) but one patient receiving naproxen had them in both the stomach and the duodenum. Only three patients (naproxen) developed upper abdominal complaints, and the rest were all asymptomatic. Prostaglandins were not suppressed in the three patients with endoscopic abnormalities due to etodolac. As mentioned above, comparable numbers of patients took other NSAIDs before receiving either naproxen or etodolac. Prior exposure to NSAIDs did not seem to affect the side effects due to the study drugs, possibly because of the washout period. Only seven patients (five naproxen, two etodolac) out of 21 (33%) previously receiving NSAIDs developed endoscopic damage on completion of the study. Prostaglandin values in such patients were not significantly different from those of other members of their respective groups. The number of patients with severe inflammation in their gastric biopsy specimens rose from three (23%) to 10 (77%) after taking naproxen, and from four (29%) to 11 (79%) after etodolac treatment. There was no correlation between prostaglandin values and the degree of gastric endoscopic damage (r = -0.3196 for prostaglandin E2, -0.3793 for prostaglandin I2, and -0.2339 for thromboxane B2 in the entire population of rheumatoid patients). Also, no significant correlation was found between the prostaglandin E2/thromboxane B2 ratio and the endoscopic scores (r = -0.2495). Both gastric and duodenal prostaglandin E2/thromboxane B2 ratios were significantly higher in patients receiving etodolac than in those who took naproxen (p < 0.005). From these results it seems that there should be some form of negative correlation between endoscopic scores and prostaglandin E2/thromboxane B2 ratios as patients receiving naproxen appear to have lower ratios and higher scores. This cannot be proved, however, as no correlations were significant.

Discussion

This study shows that, unlike naproxen, etodolac does not suppress gastric or duodenal prostaglandin synthesis. In this respect these results disagree with most of the available data obtained from studies on gastric prostaglandins in patients with rheumatic diseases or those receiving regular NSAID treatment; such studies have shown that the NSAIDs tested do suppress gastric prostaglandins.10 20 The effects of individual NSAIDs were not known in those reports, however, baseline prostaglandins were not measured, and the number of patients taking the same agent was small.

Patients receiving naproxen had both a greater number of endoscopic abnormalities and lower prostaglandin values. Possibly, these two events were interrelated, but we, like others,4 were unable to show a correlation between the endoscopic scores and prostaglandin values. Gastritis22 does not adequately explain the sparing of prostaglandin by etodolac as inflammation was present in similar numbers of patients who took either agent. The significance of this gastritis is unclear; it was not evident on endoscopic examination and was only shown by histology.

Possibly, agents like etodolac may be selective in their effects on various tissues and different types of prostaglandins. Such an effect was previously described with salicylic acid, which caused preferential reduction in prostaglandin E2 in sheep vesicular tissue, whereas indomethacin suppressed all classes of prostaglandins.21

The fact that prostaglandins were not suppressed in patients who developed endoscopic abnormalities due to etodolac may mean that the mucosa was not affected by NSAIDs before full healing of erosions, though we have not shown that such capacity was lost to begin with, or that mechanisms other than prostaglandin deficiency were involved in causing gastric damage: in theory, these could include increased mucosal permeability,22 interference with active ion transport,23 redistribution of mucosal blood flow,24 capillary stasis,25 or interference with the mucus layer.26

Little is known about the duodenal mucosal prostaglandin response to the intake of NSAIDs as most studies have concentrated on their effect on the gastric mucosa,3 5 6 8 9 possibly owing to the fact that the stomach is more commonly affected by NSAIDs than the duodenum as shown by this study and by others.27 Like one of the previous studies on patients with duodenal ulcers,28 our results may suggest that the duodenal mucosal potential to synthesise prostaglandin I2 decreases in the presence of ulceration or when subjected to naproxen. Duodenal prostaglandin E2 was also suppressed in our patients taking naproxen, but not in those of Hillier et al.,28 the difference probably being due to the fact that their patients did not take NSAIDs. It is also interesting to find that patients who took naproxen had higher values of thromboxane B2 (the stable metabolite of thromboxane A2) than those receiving etodolac. Animal studies have suggested that vasodilatation with thromboxane A2 induces ulceration of the gastric mucosa,29 and that the selective inhibition of its synthesis results in gastric mucosal protection.30 The effect of thromboxane A2 on the duodenal mucosa was not clarified by those studies. We found that both gastric and duodenal prostaglandin E2/thromboxane B2 ratios were higher in patients taking etodolac than in those receiving naproxen. The significance of this is not fully clear but it may explain, at least in part, the greater damaging effects of naproxen, though we could not show a significant correlation between the prostaglandin E2/thromboxane B2 ratio and the endoscopic scores.

In conclusion, after four weeks of regular intake in therapeutic doses, naproxen suppressed gastric prostaglandin E2, duodenal prostaglandin E2 and prostaglandin I2, while etodolac did not. At the same time etodolac caused a lesser degree of endoscopic damage than naproxen; this may be related to their different effects on prostaglandins, though there was no correlation between prostaglandin values and endoscopic scores. If it is assumed that more
NSAIDs are assessed along the same lines as our study and would behave similarly to either naproxen or etodolac, our results may indicate that not all NSAIDs suppress gastric or duodenal prostaglandins. Other modes of interaction between NSAIDs and the gastroduodenal mucosa need to be investigated.

We are very grateful to Wyeth Laboratories for providing the study drugs and financial support. We also thank Miss Margaret Black for her secretarial assistance.

Effect on gastric and duodenal mucosal prostaglandins of repeated intake of therapeutic doses of naproxen and etodolac in rheumatoid arthritis.

A S Taha, S McLaughlin, P J Holland, R W Kelly, R D Sturrock and R I Russell

doi: 10.1136/ard.49.6.354

Updated information and services can be found at:
http://ard.bmj.com/content/49/6/354

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/